mCig Inc (OTCMKTS:MCIG) is among the very few companies in the expansive marijuana industry without any toxic debt an advantaged enjoyed by few players in the business. Investments have been forthcoming as the company moves to affirm its foothold in the fast growing business. Having sealed a $1.2 million CBD product order mCig has affirmed its position as a go-to place for technologies and solutions in the legal, medical marijuana industry.

Improved Production

The acquisition of two large cannabis farms in Oregon should allow the company to furnish the orders without any problems. Production capacity is expected to improve going forward, especially on the acquisition of a new subsidiary Canna Pro Tech.

mCig Inc (OTCMKTS:MCIG) also has on its ranks a patented cannabis extraction method that highlights how the company is slowly becoming self-sufficient as it moves to diversify its sources of revenue. The patented technology could generate a substantial amount of revenue going forward as the company moves to market it to other players in the marijuana business.

mCig is A Long Term Play

Current investors may not be able to generate enough value from the stock as the company continues to divert most of its profits to investments, expected to generate value in the long term. The model has allowed mCig to stay clear of ‘toxic debts’ synonymous with its peers. The hiring of a global sales manager also highlights the company’s vision to ramp up sales in emerging markets.

mCig Inc (OTCMKTS:MCIG) is aggressively developing and launching new products as it looks to generate revenues in the range of $7 million and $10 million this year. Plans are already in place to bring to market a new exciting organic product EM-J infused with Cannabidiol. mCig has also begun production for its first ever Supercritical CO2 extraction unit as it moves to produce commercial grade products for customers.